Allay Therapeutics is pioneering a novel approach to pain management through its proprietary technology platform, which combines validated non-opioid analgesics with biopolymers. This innovative architecture allows for the creation of dissolvable therapeutic candidates that deliver targeted pain relief over extended periods, significantly longer than traditional treatments. The platform is designed to provide ultra-sustained and predictable release of analgesics, aligning with the natural recovery trajectory of patients. For instance, their investigational product ATX-101 is specifically designed for post-surgical pain management, particularly following total knee replacement surgery, and can provide pain relief for weeks with minimal systemic exposure.

The technology aims to address the limitations of systemic analgesics, such as opioids, which are associated with significant side effects and risks of dependence. By focusing on localized pain relief, Allay's products, like ATX-101, utilize bupivacaine to inhibit pain signals directly at the surgical site, thereby reducing the need for constant re-dosing and clinical oversight. This approach not only enhances patient comfort and recovery but also offers economic benefits for healthcare systems by potentially lowering rehabilitation costs and reducing readmissions. Overall, Allay Therapeutics is positioned to transform the landscape of post-surgical pain management through its innovative, non-opioid solutions.

United States

Allay Therapeutics is pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation for patients and physicians. 

We believe an era of stalled innovation for pain management is over. From San Francisco to Singapore, our team has a passion for solving medical challenges that could benefit millions. We pursue our mission with the energy of a dynamic, global team of entrepreneurs, scientists, clinicians and innovators.


Allay Therapeutics

Company Details